NDATOPICALCREAMPriority Review
Approved
Jan 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SULFAMYLON (mafenide acetate) is a topical cream antibiotic agent approved in 1969 for the treatment of burn wounds and severe skin injuries. It penetrates eschar and is used to prevent and treat bacterial infection in second and third-degree burns. The drug works as a broad-spectrum antimicrobial that inhibits bacterial protein synthesis.
$0.052MPart D
LOE ApproachingMature, legacy product with minimal growth potential; team size likely small and focused on brand defense and market maintenance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SULFAMYLON offers minimal career mobility and growth potential; the product is a mature, legacy burn care therapy with no linked job openings and approaching loss of exclusivity. Professionals assigned to this brand should expect a defensive, maintenance-focused role with limited visibility and advancement opportunities compared to growth-stage portfolios.
Brand Manager
Worked on SULFAMYLON at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.